Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilles Paintaud

Showing results (61-70 of 125) with videos related to

Pageof 13
Sort By:
European Journal of Clinical Pharmacology|March 1, 2002
Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategyChantal Le Guellec, Matthias Büchler, Bruno Giraudeau, et al.
Clinical Pharmacokinetics|July 22, 2021
Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant PatientsNicolas Azzopardi, Hélène Longuet, David Ternant, et al.
Clinical Pharmacokinetics|July 10, 2016
Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV StudyFrancis Lévi, Abdoulaye Karaboué, Marie-Christine Etienne-Grimaldi, et al.
Inflammatory Bowel Diseases|May 23, 2018
Modeling Immunization To Infliximab in Children With Crohn's Disease Using Population Pharmacokinetics: A Pilot StudyAntoine Petitcollin, Oriane Leuret, Camille Tron, et al.
Clinical Pharmacology and Therapeutics|February 6, 2021
Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal AdministrationOlivier Le Tilly, Nicolas Azzopardi, Claire Bonneau, et al.
Blood|November 26, 2008
Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20David Daydé, David Ternant, Marc Ohresser, et al.
Mabs|September 3, 2016
The underlying inflammatory chronic disease influences infliximab pharmacokineticsChristophe Passot, Denis Mulleman, Theodora Bejan-Angoulvant, et al.
Clinical Pharmacokinetics|August 14, 2025
Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab PharmacokineticsDavid Ternant, Olivier Le Tilly, Guillaume Cartron, et al.
Therapeutic Drug Monitoring|March 11, 2010
Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritisDenis Mulleman, Delphine Chu Miow Lin, Emilie Ducourau, et al.
Fundamental & Clinical Pharmacology|February 2, 2006
Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0Cécile Loichot, Danièle Bentue-Ferrer, Nicole Bernard, et al.
Pageof 13

Showing results (61-70 of 125) with videos related to

Sort By:
Pageof 13
European Journal of Clinical Pharmacology|March 1, 2002
Simultaneous estimation of cyclosporin and mycophenolic acid areas under the curve in stable renal transplant patients using a limited sampling strategyChantal Le Guellec, Matthias Büchler, Bruno Giraudeau, et al.
Clinical Pharmacokinetics|July 22, 2021
Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant PatientsNicolas Azzopardi, Hélène Longuet, David Ternant, et al.
Clinical Pharmacokinetics|July 10, 2016
Pharmacokinetics of Irinotecan, Oxaliplatin and 5-Fluorouracil During Hepatic Artery Chronomodulated Infusion: A Translational European OPTILIV StudyFrancis Lévi, Abdoulaye Karaboué, Marie-Christine Etienne-Grimaldi, et al.
Inflammatory Bowel Diseases|May 23, 2018
Modeling Immunization To Infliximab in Children With Crohn's Disease Using Population Pharmacokinetics: A Pilot StudyAntoine Petitcollin, Oriane Leuret, Camille Tron, et al.
Clinical Pharmacology and Therapeutics|February 6, 2021
Antigen Mass May Influence Trastuzumab Concentrations in Cerebrospinal Fluid After Intrathecal AdministrationOlivier Le Tilly, Nicolas Azzopardi, Claire Bonneau, et al.
Blood|November 26, 2008
Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20David Daydé, David Ternant, Marc Ohresser, et al.
Mabs|September 3, 2016
The underlying inflammatory chronic disease influences infliximab pharmacokineticsChristophe Passot, Denis Mulleman, Theodora Bejan-Angoulvant, et al.
Clinical Pharmacokinetics|August 14, 2025
Immunoglobulin G Receptors (FcγR), in Addition to Target-Antigen and Neonatal Fc Receptor (FcRn), Influence Rituximab PharmacokineticsDavid Ternant, Olivier Le Tilly, Guillaume Cartron, et al.
Therapeutic Drug Monitoring|March 11, 2010
Trough infliximab concentrations predict efficacy and sustained control of disease activity in rheumatoid arthritisDenis Mulleman, Delphine Chu Miow Lin, Emilie Ducourau, et al.
Fundamental & Clinical Pharmacology|February 2, 2006
Cyclosporine monitoring in renal transplant recipients with induction therapy: C2 levels in patients monitored on C0Cécile Loichot, Danièle Bentue-Ferrer, Nicole Bernard, et al.
Pageof 13